Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
NTRA reports proposed sales of Common shares under a Form 144 filing, showing multiple dispositions by an affiliate. The filing lists transactions by Jonathan Sheena, including sales of 2,981 shares on 01/20/2026 for $699,755.00, 3,070 shares on 03/02/2026 for $614,710.00, and 3,070 shares on 03/18/2026 for $608,370.00.
The entries show individual sale dates, share counts, and gross proceeds; they record routine reported dispositions rather than company actions. The broker/transfer line shows Charles Schwab & Co., Inc. as the clearing broker in the excerpt.
Jonathan Sheena submitted a Rule 144 notice proposing sales of Common stock previously acquired. The filing lists multiple disposition dates and share amounts as examples, including 3,163 shares on 01/21/2026 and 3,070 shares on 03/02/2026. The sales were processed through Charles Schwab & Co., Inc.
Natera, Inc. director Rowan E. Chapman sold 122 shares of Common Stock in an open-market transaction at $191.38 per share. The sale occurred on March 13, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025.
Following this sale, Chapman directly holds 5,752 Natera shares, indicating that the transaction covers only a small portion of his reported stake.
Natera, Inc. executive chairman Matthew Rabinowitz exercised stock options to acquire 200,000 shares of common stock at an exercise price of $9.59 per share, then sold 200,000 shares in multiple open-market transactions. The sales were executed at weighted average prices generally between about $186 and $198 per share.
According to the filing, all sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, Rabinowitz directly holds 2,310,772 shares of Natera common stock, with an additional 5,000 shares held indirectly by his spouse.
Natera, Inc. chief financial officer Michael Burkes Brophy reported two stock transactions. On March 9, 2026, he received 1,968 fully vested RSUs, each representing one share of common stock, as a stock award with no cash paid per share.
On March 10, 2026, he sold 785 shares of common stock at $204.1327 per share to cover tax withholding and remittance obligations related to the RSU vesting, under written instructions intended to satisfy Rule 10b5-1(c). After these transactions, he directly held 63,354 shares of Natera common stock.
Natera, Inc. CEO and president Steven Leonard Chapman reported a compensation-related share grant and a linked sale. On March 9, 2026, he received 5,623 fully vested Restricted Stock Units (RSUs), each representing one share of common stock. On March 10, 2026, he executed an open-market sale of 5,623 shares at an average price of $204.1327 per share, with the sale described as being partially to satisfy tax withholding obligations and carried out under a written instruction intended to meet Rule 10b5-1(c) conditions. After these transactions, he directly holds 156,607 shares of Natera common stock.
Natera, Inc. executive Daniel Rabinowitz, the Secretary and Chief Legal Officer, reported routine equity compensation activity and related share sales. He received a fully vested grant of 1,745 Restricted Stock Units, each representing one share of common stock. The next day, he sold 1,745 common shares in an open-market transaction at an average price of $204.1327 per share, leaving him with 233,285 shares of common stock held directly after the sale.
According to the disclosure, the sale was partially conducted to cover tax withholding and remittance obligations tied to the RSU vesting and was executed under written instructions intended to qualify for the Rule 10b5-1(c) affirmative defense, indicating a pre-arranged trading framework rather than an opportunistic trade.
Natera, Inc. director and co-founder Sheena Jonathan reported a small mix of stock compensation and related tax selling. On March 9, 2026, she received 258 shares of Common Stock as fully vested Restricted Stock Units granted at $0.0000 per share.
On March 10, 2026, she sold 127 shares of Common Stock at an average price of $204.1327 per share. The filing states this sale was made to satisfy tax withholding and remittance obligations tied to the RSU vesting and was executed under written instructions intended to qualify under Rule 10b5‑1. After these transactions, she directly owned 262,325 shares of Common Stock, with additional shares held in Caraluna 1 Trust and Caraluna 2 Trust for which she disclaims beneficial ownership.